Prognostic Value of Thyroid Transcription Factor-1 Expression in Patients with Advanced Lung Adenocarcinoma

Zablockis, Rolandas; Žurauskas, Edvardas; Danila, Edvardas; Gruslys, Vygantas

doi:10.21873/invivo.11416

Cited by 5 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed an inverse correlation between TTF‐1 expression and EGFR mutation in advanced LUAD patients, which is consistent with previous studies that have demonstrated the rarity of EGFR mutations in TTF‐1‐negative LUAD 19,23,24 . In our cohort, only 26.6% of the TTF‐1‐negative patients had EGFR mutations, which is lower than the 32.1% reported by Chung et al, but higher than 2.6% and 6%, respectively, reported by Zablockis and Schilsky, possibly due to selection bias 19,23,24 . Thus, the absence of TTF‐1 immunoreactivity can reliably predict the absence of activating EGFR mutations.…”

Section: Discussionsupporting

confidence: 92%

“…Consistent with this, inhibition of TTF‐1 through RNA interference in adenocarcinoma cell lines has been shown to significantly inhibit tumor growth and induce apoptosis 18 . On the other hand, some studies have shown that TTF‐1 is associated with prolonged survival of patients with LUAD 19,20 . In fact, there is substantial evidence suggesting that TTF‐1 has a paradoxical tumor‐suppressive function.…”

Section: Discussionmentioning

confidence: 75%

See 1 more Smart Citation

Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations

Ding,

Shi,

Han

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThe absence of thyroid transcription factor 1 (TTF‐1) is associated with a lower frequency of epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma (LUAD). The aim of this study was to assess the impact of TTF‐1 expression on the clinical response to EGFR‐tyrosine kinase inhibitor (TKI) treatment in patients with advanced LUAD.MethodsThe data of patients with advanced LUAD who were admitted to the Beijing Tiantan Hospital and Peking University Cancer Hospital (China) between April 2009 and May 2023 was retrospectively analyzed.ResultsA total of 227 patients diagnosed with advanced LUAD were included, of which 28.2% (64/227) had TTF‐1‐negative adenocarcinoma, while 54.6% (124/227) harbored EGFR mutations. Negative TTF‐1 expression significantly correlated with male sex (68.8% vs. 42.3%, p < 0.001), history of heavy smoking (57.8% vs. 36.2%, p = 0.003), poorly differentiated tumors (86.5% vs. 43.2%, p < 0.001), and lower frequency of EGFR mutations (26.6% vs. 65.6%, p < 0.001) compared with TTF‐1 positivity. Multivariable logistic regression showed that low prevalence of EGFR mutations (p < 0.001) and male sex (p = 0.006) were independent predictive factors for the negative expression of TTF‐1. Patients lacking TTF‐1 also exhibited worse overall response rate (ORR; 23.5% vs. 54.2%, p = 0.019), disease control rate (DCR; 58.8% vs. 89.7%, p = 0.003), and median progression‐free survival (PFS; 2.9 vs. 11.6 months, p < 0.001) following treatment with EGFR‐TKIs compared to the TTF‐1‐positive patients with EGFR mutations.ConclusionsPatients with TTF‐1‐negative and EGFR‐mutant LUAD show a diminished response to EGFR‐TKIs.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 75%

Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations

Ding,

Shi,

Han

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…[ 6 ] Zablockis et al revealed a significant prognostic role of thyroid TF-1 expression in patients with advanced lung adenocarcinoma. [ 7 ] Wu et al suggested that spalt-like TF 4 served as a potential diagnostic and prognostic biomarker of colorectal cancer. [ 8 ] Zhang et al indicated that lack of caudal-type homeobox TF 2 expression functioned as a prognostic biomarker in metastatic colorectal carcinoma.…”

Section: Introductionmentioning

confidence: 99%

“…For instance, Hirao et al reported that TF homeobox D9 was associated with the malignant phenotype of cervical cancer via direct binding to the human papillomavirus oncogene promoter [6] . Zablockis et al revealed a significant prognostic role of thyroid TF-1 expression in patients with advanced lung adenocarcinoma [7] . Wu et al suggested that spalt-like TF 4 served as a potential diagnostic and prognostic biomarker of colorectal cancer [8] .…”

Section: Introductionmentioning

confidence: 99%

A 6 transcription factors-associated nomogram predicts the recurrence-free survival of thyroid papillary carcinoma

Wang

Tian²,

Xie³

et al. 2021

Medicine

View full text Add to dashboard Cite

Various researches demonstrated that transcription factors (TFs) played a crucial role in the progression and prognosis of cancer. However, few studies indicated that TFs were independent biomarkers for the prognosis of thyroid papillary carcinoma (TPC). Our aim was to establish and validate a novel TF signature for the prediction of TPC patients’ recurrence-free survival (RFS) from The Cancer Genome Atlas (TCGA) database to improve the prediction of survival in TPC patients. The genes expression data and corresponding clinical information for TPC were obtained from TCGA database. In total, 722 TFs and 545 TPC patients with eligible clinical information were determined to build a novel TF signature. All TFs were included in a univariate Cox regression model. Then, the least absolute shrinkage and selection operator Cox regression model was employed to identify candidate TFs relevant to TPC patients’ RFS. Finally, multivariate Cox regression was conducted via the candidate TFs for the selection of the TF signatures in the RFS assessment of TPC patients. We identified 6 TFs that were related to TPC patients’ RFS. Receiver operating characteristic analysis was performed in training, validation, and whole datasets, we verified the high capacity of the 6-TF panel for predicting TPC patients’ RFS (AUC at 1, 3, and 5 years were 0.880, 0.934, and 0.868, respectively, in training dataset; 0.760, 0.737, and 0.726, respectively, in validation dataset; and 0.777, 0.776, and 0.761, respectively, in entire dataset). The result of Kaplan–Meier analysis suggested that the TPC patients with low scores had longer RFS than the TPC patients with high score ( P = .003). A similar outcome was displayed in the validation dataset ( P = .001) and the entire dataset ( P = 2e-05). In addition, a nomogram was conducted through risk score, cancer status, C-index, receiver operating characteristic, and the calibration plots analysis implied good value and clinical utility of the nomogram. We constructed and validated a novel 6-TF signature-based nomogram for predicting the RFS of TPC patients.

show abstract

“…4 To make matters worse, the majority of lung cancer patients are usually diagnosed at a late stage when a tumor has started to metastasize. 5 Although the prognosis of LAC has improved with the advent of targeted drugs, the mortalities of LAC patients are still high as a result of a lack of effective prognostic and diagnostic biomarkers. 6 Hence, it is necessary to fully illustrate good prognostic indicators to guide the treatment and clinical management of LAC patients.…”

Section: Introductionmentioning

confidence: 99%

LncRNA LINC00511 plays an oncogenic role in lung adenocarcinoma by regulating PKM2 expression via sponging miR‐625‐5p

Xue

Zhang

2020

Thoracic Cancer

View full text Add to dashboard Cite

Background Lung adenocarcinoma (LAC) is the most prominent histological subtype of non‐small cell lung cancer (NSCLC) with a high rate of mortality and metastasis. Accumulating evidence has shown that long non‐coding RNAs (lncRNAs) play malfunctioning roles in the development of human tumors. Hence, this study aimed to determine the biological function of LINC00511 in LAC and to provide a novel diagnostic and therapeutic target for it. Methods LINC00511 expression in LAC tissues and cell lines (H1299 and A549) were detected by real time‐polymerase chain reaction (RT‐qPCR). Cell counting kit‐8 (CCK‐8) assay was employed to analyze cell proliferative ability. Cell metastasis change was measured using transwell assay. Moreover, we revealed a novel target gene of LINC00511 and elucidated the underlying competitive endogenous RNA regulatory mechanism in LAC cells. Results Data from our study demonstrated that LINC00511 expression was increased in LAC tissues and cells in comparison to their corresponding controls. Moreover, overexpression of LINC00511 indicated the poor prognosis of LAC patients. Overexpression of LINC00511 promoted proliferation, invasion and migration capacities of LAC cells. Moreover, LINC00511 promoted LAC progression via serving as a sponge of miR‐625‐5p and regulating PKM2 expression. Conclusions The present study showed that LINC00511 was involved in LAC progression by targeting miR‐625‐5p/PKM2, indicating that LINC00511/miR‐625‐5p/PKM2 may function as promising therapeutic targets for LAC.

show abstract

Prognostic Value of Thyroid Transcription Factor-1 Expression in Patients with Advanced Lung Adenocarcinoma

Cited by 5 publications

References 34 publications

Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations

Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations

A 6 transcription factors-associated nomogram predicts the recurrence-free survival of thyroid papillary carcinoma

LncRNA LINC00511 plays an oncogenic role in lung adenocarcinoma by regulating PKM2 expression via sponging miR‐625‐5p

Contact Info

Product

Resources

About